An International, Phase 3, Open-label, Randomized Study of BGB-3111 Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
*For Eligibility information, look up the trial at NIH by clicking on the Study Number above.*
Other eligibility criteria may apply.
Other exclusion criteria may apply.